univers coverag
calendar event
medacorp event updat advanc dmd sma muscl
medic meet american medic associ associ profession infect
control epidemiolog european leagu rheumat
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
gov lose t-twx close without condit posit pbm-mco
bottom line highli anticip t-twx court decis favor compani
doj meaning increas probabl two vertic mega-merg
close aet mp esrx mp trade meaning close op ci op
slightli expect spread target aet esrx continu narrow come day
afternoon highli anticip t-twx court decis rule favor compani
deal set close without condit
t-twx preced set posit read-across ci-esrx aet-cv
spread target esrx aet continu narrow come day view
pleas see link two medacorp anti-trust specialist call aet-cv link
ci-esrx deal link
pleas see link file analysi deal cvs-aet link ci-esrx link
pleas see call post boston investor meet ci cfo eric palmer link
t-twx approv bode pend ci-esrx cvs-aet deal
bottom line tuesday afternoon judg richard leon reject doj lawsuit attempt block
t-twx deal judg leon effect approv deal without requir asset divestitur
remedi sever differ t-twx pend op -aet
mp ci op -esrx mp deal believ preced set t-twx case bode well
pend deal light rule revisit esrx determin stock
may behav without regulatori approv doj previous request divestitur
directv turner asset remedi competit concern also revisit overlap
medicar part market doj current anti-trust chief makan delrahim vocal critic
behavior remedi support asset divestitur overal continu believ
chanc deal close
estim downsid risk esrx materi deal block
overlap medicar part market still area concern
harm consum focu anti-trust regul burden lie doj
link previou medacorp puls call note link link
hh secretari azar keep pressur
bottom line tuesday hh secretari azar testifi senat health educ
labor pension help committe discuss trump administr recent drug price
blueprint hear larg focus mani topic featur blueprint
detail previou note link mr azar reiter administr four main focus
high list price drug senior govern program overpay drug high
rise out-of-pocket cost consum foreign govern free-rid american
innov well mr azar spoke transit payment model rebat system
base list price one base fix rate up-front discount overal continu believ
chang sought take time implement pbm distributor abl
util strategi process reduc unfavor impact propos polici chang
surpris commit secretari seem get rid rebat sound like may
need congress pass law allow alter safe harbor provis commerci
hh appear readi take action continu express reconciliatori tone seek
help congress
pbm may abl mitig exposur chang safe harbor
distributor would like face impact reduc list price increas
outperform market cap price price target methodolog dcf
cash flow use wacc
bottom line heron report result two studi end month phase ii studi
total knee arthroplasti tka instal phase iib studi breast augment instal
nerv block data import provid pk/pd data two addit
surgic model requir part submiss packag instal posit tka
studi go long way support commerci effort pain orthoped surgeri
tka posit breast augment studi provid initi proof concept nerv
block pull back last week investor concern around result
note highlight believ studi good chanc work get two
posit studi could see upsid stock see less downsid current level
studi posit get mix result recent pull-back stock
even tka studi work necessari approv heron still option
conduct anoth larger studi better power prior launch nerv block
rel smaller opportun compar instal reiter op
believ tka studi good chanc success weigh posit risk
look tka studi hit primari end point
breast augment studi see posit risk note expect low
head data readout
puerto rico medicaid award expect late june earli juli
bottom line puerto rico expect award medicaid manag care contract late june
earli juli coverag op incumb membership market share
puerto rico gener total revenu compani gener mm
premium revenu estim loss mm oper earn puerto rico
lower averag pmpm new three-year contract anticip go-liv
octob dictat puerto rico move oper model mco must provid
coverag across territori one region sixteen total entiti respond rfp includ
incumb publicli trade op nr key upcom catalyst
pr award risk adjust data juli earn tx award octob
puerto rico expect award medicaid manag care contract late june earli juli
incumb
triple- first medic incumb
entiti submit respons rfp dictat mco must bid island-wid coverag
incumb bid includ well publicli trade
upcom catalyst pr award risk adjust data juli earn tx
award octob
fda breath life gener advair time
of-the-part weight average ev/ebitda multipl
bottom line june pass gdufa date gx advair
us sale advair signific opportun like competitor
could alon first month manag appear confid head
gdufa date ignor complex around get gener respiratori product
approv nevertheless approv complex gener clearli prioriti fda
see approv matter current estim risk-
adjust po sale gx advair translat ep
contribut pt day follow announc biosimilar
neulasta approv would expect greater stock reaction gx advair get green
light two week believ stock current level reflect uncertainti around
time approv gener advair reiter op
complex road approv look good posit
posit first-to-market us market limit competit
sotp impli ev/sal
bottom line remain long-term bull believ sinuva potenti key
growth acceler sourc estim upsid out-year said acknowledg
set-up look great acknowledg stock could volatil recommend
buy share weak next month amid heighten state anxieti
exist sinc may stem uncertainti around establish perman j-code
view may shape in-linish -- -base intra-qtr management commentari investor
confer reiter expect base biz slowdown sinuva distract rep time
earli sinuva medacorp check suggest although sinuva reimburs approv rate
encouragingli track rang pre-author process appear take bit
longer expect week instanc maintain op rate pt
expect stock volatil come month evidenc pullback
attribut investor learn process interview nation director
turn sinuva initi medacorp ent check suggest take anywher week
get sinuva pre-author process sinuva see approv rate
slightli longer-than-expect pre-author process could mean limit upsid potenti
consensu estim dont see big risk hit full-year sinuva revenue forecast
expect around base biz recal management full-year outlook impli
slowdown growth trajectori -- -which we/consensu alreadi model
updat polici increment posit
bottom line last night close announc updat coverag polici
allow medicar patient util smartphon data read dxcm essenti eas
restrict forc patient use receiv improv dxcm competit posit vs
mp libr popul us announc come bit earlier expect
believ street investor contempl polici updat year
leav revenu estim unchang y/i y/
think announc could skew number upsid rate outperform
addit reimburs code posit upsid estim
bottom line announc today receiv approv payment deletion/
duplic analysi code conjunct alreadi exist code
medicar medicar account hereditari cancer test volum assum
volum hereditari breast ovarian cancer hboc result see
hboc volum could see uplift addit payment beyond exist
medicar payment code see posit base
addit code expect hboc volum see upsid revenu
beyond street estim could doubl hboc volum
though benefit like come year rate unlik retroact
still see posit go forward rate outperform
bio-brand eros biosimilar fresh analysi suggest new
kkr acquir evhc arm race ambulatori asset like continu
unexpect controversi quick prelim thought
ev/sal support dcf use wacc long-term growth rate
expect report preliminari updat first clinic data
micro-dystrophin candid earn call management establish threshold
accept micro-dystrophin express suggest would repres
versu eteplirsen exon skip-amen duchenn muscular dystrophy/dmd
golodirsen exon dystrophin express level higher
could confer robust function clinic benefit pt
preclin data gene therapi construct present although note
lower dose sarepta/genethon construct produc express
lower dose solid bioscienc construct produc express dmd dog
think good potenti upsid home run level set
compani develop microdystrophin gene therapi dmd
competit acquir bamboo op
solid clinic hold still place sarepta could potenti first-to-market
decemb akao report posit top-lin data two phase studi epic
expect support registr expect primari driver
commerci adopt
epic recruit patient suspect complic urinari tract infect cuti
demonstr plazomicin statist non-inferior meropenem fda primari
endpoint statist superior three key efficaci measur includ ema
primari outcom test cure
see nich role plazo treatment-refractori cuti expect drug
primari clinic util carbapenem-resist enterobacteriacea support
compel data studi albeit small sampl show
reduct death/seri complic mortal respect rel
activ control
continu project peak sale plazomicin ww us sale
row royalti us sale come base upon trajectori
agn avycaz accord medacorp kol gener major sale
off-label use infect
despit regulatori process drag manag re-affirmed confid
april investor day see link takeaway approv ahead june
criteria demonstr same appear rigor respond
everi inform request fda issu point believ
outstand scientif issu product
manufactur gener begun compani would readi launch
new product launch key offset continu pressur us gener
kol specialist takeaway link global healthcar confer support
view obtain approv like see limit competit
estim gener advair revenu
account potenti competitor delay
next import catalyst alder six month data ph pivot trial
chronic migrain due second quarter
trial expect provid extend durat repeat dose safeti efficaci
month
data expect includ bla eptinezumab need
consist earlier announc data free increas new
advers event increas neutral antibodi
augment trial approach complet top-lin result releas
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
post-op pain tka breast augment ph iib data
strong ph top-lin result post-op pain earlier believ
larg de-risk ahead nda submiss potenti approv
howev also expect see phase iib result total knee arthroplasti
tka instil breast augment instil nerv block
believ stock fulli reflect peak potenti given
potenti best-in-class profil non-opioid altern post-op pain manag
estim revenu post-op indic
announc final patient dravet studi complet dose
may expect report top-lin data trial late june earli juli
dravet syndrom present signific unmet medic need compel clinic
data first two dravet studi render investor physician
patient excit potenti drug
initi phase studi demonstr unpreced level seizur
reduct dravet patient
initi roll nda base result two phase dravet
studi data avail open-label extens suffici
patient exposur support safeti requir file
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
one regn import catalyst approv antibodi cemiplimab
cutan squamou cell carcinoma cscc
compani pdufa date octob research suggest first approv
checkpoint antibodi new indic typic come ahead pdufa date like
june juli cemiplimab estim
particularli true applic benefit breakthrough design
prioriti review case cemiplimab
regeneron also appear signal expect approv occur earlier
date confirm us commerci team readi launch product
immedi avail channel
project peak pos-adjust us cemiplimab sale
expect secur fda approv eversens continu glucos
monitor cgm believ nearli total address market
us alon
view eversens appeal broad patient popul encompass
type current declin cgm option due high burden therapi
patient also type reason
alreadi receiv approv eversens eversens xl
europ eversens xl launch uk sweden expect
transit eversens xl europ market
regard us product launch current employe us
commerci team -- readi launch eversens upon fda approv --
compani plan doubl team
fda panel vote unanim favor cgm approv march
believ us approv question
near term secur fda approv eversens time dose claim
like next major catalyst stock
current project us eversens sale
near term secur fda approv eversens time dose claim
like next major catalyst stock
earlier may report on-going phase iib studi rti elderli
complet dose final patient put trial track top-lin data readout
binari name within coverag univers anticip tremend
volatil around report phase iib top-lin data
believ current impli probability-of-success po studi offer
attract invest opportun investor will accept risk inher
project ww pos-adjust revenu rti /-
note ph criteria differ nccn guidelin meant trial
result directli compar prior studi
discuss fda on-going primari endpoint determin
told endpoint may similar select ph design
link note
recent pamrevlumab result suggest convent ct scan may accur predict
resect lapc patient
success pamrevlumab neoadjuv set may depend chang resctabl
standard adopt clinic regulatori commerci endpoint
late august omadacyclin antibiot skin pneumonia adcom
key catalyst remain time-frame conven adcom potenti
aug time-frame potenti approv oct time-frame could move
view fda decis panel indic concern
link view panel public forum review posit risk/
benefit profil omadacyclin evidenc last nce antibiot pneumonia
sinc adcom conven
continu view data packag omadacyclin support approv
believ current level street underappreci valu omadacyclin
gain clariti key discuss topic brief document
releas publicli two busi day ahead adcom date
pdufa date expect octob
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
sourc leerink research compani inform factset price prior day
fda adcom anesthesiolog respiratori therapi devic
pdufa akao plazomicin complic urinari tract infect bloodstream
fda adcom joint anesthet analges drug product drug
pdufa derm hyperhidrosi excess sweat link impact
medcac panel procedur volum requir hospit heart team
member begin maintain transcathet aortic valv replac
medcac panel t-cell therapi
pdufa teva fremanezumab cgrp migrain
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa revefanacin lama copd
pdufa bremelanotid hypoact sexual desir disord fda
adcom schedul
associ profession infect control epidemiolog
european hematolog associ link note abstract arql
european academi neurolog
complex cardiovascular cathet advanc endovascular
feder clinic immunolog societi
intern societi stem cell research
societi vascular surgeri
societi nuclear medicin molecular imag
european academi allergi clinic immunolog
multi-national associ support cancer intern societi
american orthopaed societi sport medicin
american societi virolog
 highlight kol panel lung cancer io cell
 rova-t present show anoth rout failur experiment oncolog
adap -- flash manag convers highlight data pipelin progress
adap studi advanc cell dose posit safeti data pt
-- flash present highlight opportun colorect cancer
celg updat strengthen profil remark respons durabl
celg profil continu present outperform
 tazemetostat mesothelioma data opportun combin outperform
 success pamrevlumab lapc may depend endpoint paradigm shift
imdz -- flash event highlight imdz approach strategi outperform
 event highlight investig view forward ii data outperform
-- flash highlight encourag data biomark strategi gastric
-- flash updat demonstr continu safeti earli efficaci
-- flash aducanumab phase trial expand variabl endpt requir
 growth margin management stabil still lack pipelin catalyst market
 ctad medacorp call aducanumab abeta hypothesi
 state larg cap biotech sfo steadi goe
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 growth deal capac target market
biopharma praluent show mortal benefit lower take aim highest risk group
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
medic devic leerink healthcar confer panel devic penetr set
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
biopharma -- flash highlight io combin seri puls call front-lin lung
biopharma highlight io agonist checkpoint puls call updat
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
celg anoth bet car-t probabl probabl sensibl even
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 investor sleep path ip protect pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
biopharma viii partnership acquisit biopharma new top list
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 add cscc respons diseas boost /sni partnership
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
 initi adama step forward parkinson dyskinesia outperform
deal capac
moat vs
 insight april nyc hc servic day convict
 mylan upgrad valuat disconnect given diversifi busi catalyst
path outperform
 initi could adenosin inhibit unlock wave i/o
outperform
 come-back stori make survey support opu market
share assumpt outperform
 initi doubl digit growth meaning margin expans ahead
outperform
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
biopharma atop derm still without ped leerink dupi derm survey
 pbc survey suggest ocaliva safeti concern manag
 hiv survey rapid adopt biktarvi challeng outlook
hcit distribut demand shift analyt effect use
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
limit upsid link
medic suppli devic survey flu help otherwis normal volume downtick
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
medic devic survey direct posit mute hope
scph furoscix survey suggest physician optim ahead june pdufa
 ceo call focus growth outlook potenti upsid area lrp pt
medic devices-cardiolog leerink leadership seri target
outlook alpha opportun abound healthcar share
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
